EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral delivery of nanomedicine for genetic kidney disease

Yi Huang, Jonathan Wang iD, Valeria Mancino, Jessica Pham, Colette O'Grady, Hui Li, Kairui Jiang iD, Deborah Chin, Christopher Poon iD, Pei-Yin Ho, Georgina Gyarmati, János Peti-Peterdi und 2 weitere

PNAS Nexus · 30.04.2024 · 3 (5)

DOI: 10.1093/pnasnexus/pgae187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PNAS Nexus, online erschienen am 10.05.2024. Verfasst von Yi Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, University of Southern California.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic and genetic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD) have few therapeutic options, and clinical trials testing small molecule drugs have been unfavorable due to low kidney bioavailability and adverse side effects. Although nanoparticles can be designed to deliver drugs directly to the diseased site, there are no kidney-targeted nanomedicines clinically available, and most FDA-approved nanoparticles are administered intravenously which is not ideal for chronic diseases. To meet these challenges of chronic diseases, we developed a biomaterials-based strategy using chitosan particles (CP) for oral delivery of therapeutic, kidney-targeting peptide amphiphile micelles (KMs). We hypothesized that encapsuling KMs into CP would enhance the bioavailability of KMs upon oral administration given the high stability of chitosan in acidic conditions and mucoadhesive properties enabling absorption within the intestines. To test this, we evaluated the mechanism of KM access to the kidneys via intravital imaging and investigated the KM biodistribution in a porcine model. Next, we loaded KMs carrying the ADPKD drug metformin into CP (KM-CP-met) and measured in vitro therapeutic effect. Upon oral administration in vivo, KM-CP-met showed significantly greater bioavailability and accumulation in the kidneys as compared to KM only or free drug. As such, KM-CP-met treatment in ADPKD mice (Pkd1fl/fl;Pax8-rtTA;Tet-O-Cre which develops the disease over 120 days and mimics the slow development of ADPKD) showed enhanced therapeutic efficacy without affecting safety despite repeated treatment. Herein, we demonstrate the potential of KM-CP as a nanomedicine strategy for oral delivery for the long-term treatment of chronic kidney diseases.

Schlagwörter

Stichwörter der Autor:innen

chronic diseasedrug deliverykidney targetingnanomedicineoral delivery

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
  • Department of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
  • USC/UKRO Kidney Research Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
  • Department of Physiology and Neuroscience, and Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA 90033, USA.
  • Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA.
  • Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

ORCID-Profile: Jonathan Wang, Kairui Jiang, Christopher Poon, Eun Ji Chung

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • University of Southern California
  • Alfred E. Mann Institute
  • New Innovator Award
  • NSF EAGER
  • WISE Major Support Award
  • National Institutes of Health

Zitieren

APA

Huang, Y., Wang, J., Mancino, V., Pham, J., O'Grady, C., Li, H., Jiang, K., Chin, D., Poon, C., Ho, P. Y., Gyarmati, G., Peti-Peterdi, J., Hallows, K. R., & Chung, E. J. (2024). Oral delivery of nanomedicine for genetic kidney disease. PNAS Nexus, 3(5). https://doi.org/10.1093/pnasnexus/pgae187

Vancouver

Huang Y, Wang J, Mancino V, Pham J, O'Grady C, Li H, et al. Oral delivery of nanomedicine for genetic kidney disease. PNAS Nexus. 2024;3(5). doi:10.1093/pnasnexus/pgae187

BibTeX
@article{Huang2024,
  author = {Huang, Yi and Wang, Jonathan and Mancino, Valeria and Pham, Jessica and O'Grady, Colette and Li, Hui and Jiang, Kairui and Chin, Deborah and Poon, Christopher and Ho, Pei-Yin and Gyarmati, Georgina and Peti-Peterdi, János and Hallows, Kenneth R and Chung, Eun Ji},
  title = {Oral delivery of nanomedicine for genetic kidney disease},
  journal = {PNAS Nexus},
  year = {2024},
  volume = {3},
  number = {5},
  doi = {10.1093/pnasnexus/pgae187}
}
Kostenlos starten →